U
Ulrich Bogdahn
Researcher at University of Regensburg
Publications - 347
Citations - 36060
Ulrich Bogdahn is an academic researcher from University of Regensburg. The author has contributed to research in topics: Neural stem cell & Neurogenesis. The author has an hindex of 67, co-authored 344 publications receiving 32279 citations. Previous affiliations of Ulrich Bogdahn include Hoffmann-La Roche & Volkswagen Foundation.
Papers
More filters
Journal ArticleDOI
Degenerative and regenerative processes in amyotrophic lateral sclerosis: motor reserve, adaptation and putative compensatory changes
Journal ArticleDOI
Relation between Laterality and Immune Response after Acute Cerebral Ischemia
TL;DR: An association between stroke laterality and immunoregulatory response in patients with acute ischemic stroke is identified and left-sided stroke may be considered as a direct risk factor for infectious disease or immune deficits and should attract special attention.
Journal ArticleDOI
Sonographic parenchymal and brain perfusion imaging: preliminary results in four patients following decompressive surgery for malignant middle cerebral artery infarct.
Felix Schlachetzki,Thilo Hoelscher,Ulrich Dorenbeck,Birgit Greiffenberg,Jörg Marienhagen,Odo-Winfried Ullrich,Ulrich Bogdahn +6 more
TL;DR: 3D-nthTCS, 3D-T CCS and LOC-TCCS are promising tools for bedside monitoring, early prognosis and treatment evaluation for MMCAI in the postoperative period.
Journal ArticleDOI
Intraventricular cytarabine in a case of idiopathic hypertrophic pachymeningitis
Ingo Kleiter,V. H. Hans,Gerhard Schuierer,Jörg Marienhagen,Peter Hau,H. Schütz,Ulrich Bogdahn,A. Steinbrecher +7 more
TL;DR: After surgical, tuberculostatic, and immunosuppressive treatment failed to control the progressive meningeal hypertrophy, causing severe headache and neurological disability, the disease process eventually abated with intraventricular cytarabine treatment.
Journal ArticleDOI
Inhibition of Smad7, a negative regulator of TGF-beta signaling, suppresses autoimmune encephalomyelitis
Ingo Kleiter,Xiomara Pedré,André M. Mueller,P. Poeschl,Sebastien Couillard-Despres,Thilo Spruss,Ulrich Bogdahn,Gerhard Giegerich,Andreas Steinbrecher +8 more
TL;DR: After systemic administration, Smad7-as ameliorated clinical signs of active and adoptively transferred EAE, diminished CNS inflammation, and reduced Smad 7 protein levels in the brain, and Smad6 inhibition thus represents a novel systemic treatment strategy for autoimmune CNS inflammation.